<DOC>
	<DOCNO>NCT00130923</DOCNO>
	<brief_summary>The purpose study compare efficacy oral risperidone ( Risperdal ) risperidone long-acting ( Consta ) reduce alcohol use person diagnose schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>Risperidone Long-acting Versus Oral Risperidone Patients With Schizophrenia Alcohol Use Disorder</brief_title>
	<detailed_description>Comorbid alcohol/substance use disorder ( SUD ) people schizophrenia major concern , view high frequency SUD among patient schizophrenia difficulty manage patient . Though antipsychotic medication effective reduce symptom impairment person schizophrenia , typical antipsychotic agent limited value control alcohol/substance use patient . Extrapyramidal , dysphoric side effect conventional neuroleptic may actually promote use substance attempt counteract effect . In addition , medication non-compliance common among patient schizophrenia . Novel antipsychotic alter treatment expectation outcomes patient severe form schizophrenia . A grow number study assess effect oral risperidone person dual disorder . Potential mechanisms action risperidone atypical antipsychotic could decrease substance use include less likely cause extrapyramidal side effect typical agent , improve negative symptom ameliorate dysfunction brain reward system . Risperidone long-acting injectable medication address issue noncompliance , avoid peak blood level oral preparation , thereby minimize EPS improve negative symptom schizophrenia . Risperidone may also facilitate dopamine neurotransmission prefrontal cortex correct hypothesize dysfunction brain reward system . This study open , randomize , control study compare intramuscular long-acting risperidone oral risperidone blind rating determine whether long-acting form risperidone great efficacy reduce substance use . Patients schizophrenia schizoaffective disorder , age 18 65 , take single oral antipsychotic medication except clozapine risperidone long-acting may enrol .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Ages 1865 Schizophrenia schizoaffective disorder Meets Structured Clinical Interview DSMIV ( SCID ) criterion alcohol use disorder Alcohol use least 5 day 4 week prior randomization Patient medically stable start either form risperidone . Current treatment clozapine . Current treatment injectable risperidone longacting . Currently pregnant , plan become pregnant , unwilling use acceptable form birth control . Change medication ( dose current medication , discontinuation medication , new medication ) past 30 day . History current breast cancer . History intolerance allergy risperidone risperidone longacting . Currently reside residential program design treat substance use disorder . Current treatment longacting , injectable antipsychotic medication require review medication adjustment group enter client study . Past treatment risperidone longacting require review medication adjustment group enter client study . Treatment baseline second antipsychotic medication require review medication adjustment group enter client study . Treatment baseline psychotropic agent propose curtail substance use require review medication adjustment group enter client study . Patients , opinion investigator , judge unsuitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Risperidone</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Substance Use Disorder</keyword>
	<keyword>Alcohol Use Disorder</keyword>
	<keyword>Treatment</keyword>
	<keyword>Schizoaffective Disorder</keyword>
</DOC>